Heghine Khachatryan: Toward Personalized Management of Glanzmann Thrombasthenia
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Journal of Thrombosis and Haemostasis (JTH)’s post on LinkedIn, adding:
“The development of antiplatelet antibodies in Glanzmann thrombasthenia remains one of the most clinically significant challenges in the long-term management of this rare inherited platelet disorder.
Beyond increasing the risk of platelet transfusion refractoriness, alloimmunization substantially complicates perioperative care and the treatment of life-threatening bleeding episodes.
Natural history data from large multicenter cohorts are therefore invaluable for identifying patients at greatest risk, optimizing transfusion strategies, and informing individualized therapeutic approaches, including the early integration of recombinant activated factor VII and emerging non-transfusion-based therapies.
This study represents an important contribution toward a more evidence-based and personalized management paradigm for patients with Glanzmann thrombasthenia.”
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Dominique Desprez et al., adding:
“Natural history of antiplatelet antibody formation in patients with Glanzmann thrombasthenia: a French multicenter prospective study
In 55 GT patients, anti-αIIbβ3 antibodies developed in 36%—mostly transient and genotype-linked—reducing fibrinogen binding but not triggering platelet damage, underscoring the value of antibody monitoring.”
Title: Natural history of antiplatelet antibody formation in patients with Glanzmann thrombasthenia: a French multicenter prospective study
Authors: Dominique Desprez, Roseline d’Oiron, Sophie Voisin, Céline Falaise, Marie-Christine Alessi, Paul Saultier, Géraldine Lavigne, Arnaud Essaydi, Marie-Joelle Apithy, Arnaud Dupuis, Valérie Goin, Yoann Huguenin, Mathieu Fiore

Other posts featuring Heghine Khachatryan and Journal of Thrombosis and Haemostasis on Hemostasis Today.
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing
-
Nov 19, 2026, 14:19Long-Read Sequencing Is Closing Diagnostic Gaps in Inherited Bleeding Disorders
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance